Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on April 9, 2009, at a price of £10.09 per share. These transactions occurred through the Company's ShareReward Plan, specifically under the Dividend Reinvestment element. The individuals involved include Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. S A Hussain, Mr. D Learmouth, Dr. D Pulman, Mr. D S Redfern, and Ms. C Thomas. Most individuals acquired 32 shares, while Mr. Hussain acquired 2 shares and Dr. Pulman acquired 14 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share purchases mentioned above.
Key Facts for Investor Verification
- Transaction Date: April 9, 2009.
- Share Price: £10.09 per Ordinary share.
- Transaction Mechanism: ShareReward Plan (Dividend Reinvestment element).
- Participants: Nine Directors or Persons Discharging Managerial Responsibility.
- Notification Date: April 14, 2009.